Twist Bioscience's Stock Sees Insider Activity Amid Financial Growth Twist Bioscience's Chief Legal Officer, Dennis Cho, sold $11,332 worth of stock to cover tax obligations. Despite this, the company projects a 19-21% revenue growth for 2025, supported by advancements in DNA synthesis and sequencing tools. Analysts have raised price targets, reflecting optimism around its financial and operational performance.12